Resources from the same session
185O - Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial
Presenter: Hope Rugo
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
186O - Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)
Presenter: Tanja Fehm
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 185O and 186O
Presenter: Gustavo Werutsky
Session: Proffered Paper session 1
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Proffered Paper session 1
Resources:
Webcast
187O - Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial
Presenter: Nicholas Turner
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
188O - EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2_ advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
Presenter: Javier Cortes
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Proffered Paper session 1
Resources:
Webcast